You have no items in your cart.
Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancers
Immuno-Oncology News
Affimed will team up with Roche to conduct a Phase 1/2a clinical trial investigating its innate cell engager AFM24 — a form of immunotherapy — in combination with Tecentriq (atezolizumab) ... Read more